Information Provided By:
Fly News Breaks for September 21, 2016
TSRO, LLY, CLVS
Sep 21, 2016 | 06:54 EDT
SunTrust analyst Peter Lawson attributes yesterday's afternoon rally in shares of Clovis Oncology (CLVS) to speculation of unconfirmed takeover interest from Eli Lilly (LLY). Clovis is a "pure play in one of the hottest areas of oncology" and could take the lead in the treatment setting in ovarian cancer for PARP inhibitors, Lawson tells investors in a research note. He expects launch of Clovis PARP inhibitor rucaparib in early 2017. The company is well positioned for upside and as a potential takeover target, Lawson contends. He finds market commentary around the PARP inhibitor companies, such as Clovis and TESARO (TSRO), as not surprising. The analyst has a Buy rating on Clovis with a $38 price target. Credit Suisse this morning upgraded the shares to Outperform citing the potential for a buyout.
News For CLVS;LLY;TSRO From the Last 2 Days
LLY
Mar 18, 2024 | 10:41 EDT
Oprah Winfrey is hosting a television special on Monday to discuss how WeightWatchers (WW) and weight loss drugs helped her with weight and obesity, CNN's Lisa Respers France reports. "An Oprah Special: Shame, Blame and the Weight Loss Revolution" will be a sit-down conversation around the "radical impact of prescription weight loss medications," according to promotional material for the special. Winfrey, who recently exited the board of WW, will moderate the conversation in front of a live audience with medical experts to explore "prevailing questions and concerns surrounding the impact on our health care, economy, lifestyle and culture," according to a press release for the event. "It is a very personal topic for me and for the hundreds of millions of people impacted around the globe who have for years struggled with weight and obesity," Winfrey said. Weight loss drug options include Eli Lilly's (LLY) Mounjaro and Novo Nordisk's (NVO) Ozempic. Reference Link